Objective: The presence of TORCH IgM positivity is not a specific indicator of primary infection; the assessment of IgG avidity index has been shown to be useful in identifying or excluding primary infection in pregnant women with no pre-gestational TORCH serology. TORCH is an acronym for Toxoplasmosis, Others (HBV, syphilis, Varicella-Zoster virus, Epstein Barr virus, Coxsackie virus and Parvovirus), Rubella, Cytomegalovirus (CMV) and Herpes Simplex. Patients and methods: Data from 54 pregnancies in women with antiphospholipid syndrome (APS) were assessed in comparison with data from 222 healthy pregnant women as controls. Each woman in both groups was systematically screened for TORCH IgG and IgM during pre-conceptional evaluation and/or at the beginning of pregnancy. The assessment of IgG avidity was also evaluated in order to identify primary infection or false positivity. Results: A significant increase of CMV IgM false positivity in APS in comparison with controls was detected. A worse pregnancy outcome was observed among APS patients having CMV IgM false positivity in comparison with APS patients without false positivity; in particular a statistically significant lower neonatal birth weight and a lower neonatal birth weight percentile were observed. Conclusion: Our data suggest that the presence of CMV IgM false positivity could represent a novel prognostic factor for poor pregnancy outcome in APS patients. Lupus (2012) 21, 773-775.
Introduction
TORCH is an acronym for Toxoplasmosis, Others (HBV, syphilis, Varicella-Zoster virus, Epstein Barr virus, Coxsackie virus and Parvovirus), Rubella, Cytomegalovirus (CMV) and Herpes Simplex. To promptly diagnose a primary infection, TORCH serology is investigated in the preconceptional period and during pregnancy: in the case of primary infection during gestation, serial laboratory and ultrasonographic follow-up studies and a specific protocol of treatments has to be established.
The TORCH IgM positivity is not always a specific indicator of primary infection in patients with autoimmune diseases, as IgM antibodies are often produced as a result of a non-specific activation of the immunological response. As previously demonstrated, a higher rate of CMV IgM false positivity was detected in pregnancies with autoimmune diseases in comparison with healthy controls. 1 Moreover, a worse pregnancy outcome was observed among patients with autoimmune diseases and CMV IgM false positivity in comparison with those without CMV IgM false positivity. 1 Regarding pregnancies with antiphospholipid syndrome (APS), TORCH IgM false positivity identified the cases with an adverse pregnancy outcome. 2 The objectives of this study were to investigate the frequency of TORCH IgM false positivity and to evaluate the role of CMV IgM false positivity as Correspondence to: Dr Sara De Carolis, Department of Obstetrics and Gynaecology, Catholic University of Sacred Heart, Largo A Gemelli 8, 00168 Rome, Italy Email: saradecarolis@libero.it a prognostic factor for poor pregnancy outcome in pregnancies in APS patients.
Patients and methods
Data from 54 pregnancies in 47 women with primary APS (PAPS) or secondary APS (sAPS), all fulfilling the revised classification criteria of APS, 3 were assessed in comparison with data from 222 healthy pregnant women controls. All APS patients were treated with conventional protocol treatment including low-dose aspirin (LDA) and low molecular weight heparin (LMWH); 4 specific treatment was established in the case of association with other autoimmune diseases. Each woman in both groups was systematically screened for TORCH IgG and IgM during the pre-conceptional assessment and/or at the beginning of pregnancy. IgG avidity was also evaluated in order to identify primary infection or false positivity. The detection of low IgG avidity in specimens from pregnant women indicates that primary infection has occurred within the past 18-20 weeks, whereas the detection of high IgG avidity excludes primary infection. 5 In the case of CMV IgM positivity, CMV isolation in maternal urine, vagina and oro-pharyngeal samples and polymerase chain reaction (PCR) for CMV-DNA in maternal urine and amniotic fluid samples were also performed. The detection of CMV IgM positivity was considered a false positive result when the CMV IgG avidity index was high, when CMV isolation was negative and when PCR for CMV-DNA on maternal urine sample or on amniotic fluid sample -when performed -were negative.
The false positive results from CMV screening were related to pregnancy outcome. The following indicators were considered for the analysis: week of delivery, neonatal birth weight and percentile and rate of babies weighing 2000 g. Student t test and Whitney-Mann test were differently used for the statistical analysis depending on the sample size and according to the shape of distribution. Cross tabulation e Chi-square (with Yates' continuity correction) were used to examine the relationship between nominal variables. p 0.05 was considered statistically significant.
Results
In the study group, pregnancies were associated with PAPS in 76% of cases (n ¼ 41) and with sAPS in 24% of cases (n ¼ 13). In APS pregnancies, the prevalence of TORCH IgM false positivity was as following: 1.9% for Toxoplasmosis, 1.9% for Rubella and 12.9% for CMV. In healthy controls the prevalence of TORCH IgM false positivity resulted: 0.5% for Toxoplasmosis, 0.5% for Rubella and 0.9% for CMV. CMV IgM false positivity was diagnosed in seven cases, including four with PAPS (57.2%) and three with sAPS (42.8%): so, it was more frequent in APS pregnancies than in healthy controls (12.9% vs. 0.9%; p < 0.0001).
In consideration of the higher rate of CMV IgM false positivity, only this parameter was related to pregnancy outcome in our analysis. As expected, a worse pregnancy outcome was shown in APS pregnancies when compared with healthy controls, excluding the two cases with CMV IgM false positivity (Table 1) .
In APS pregnancies, a poor pregnancy outcome in terms of a lower neonatal birth weight and a lower neonatal birth weight percentile was observed among women with CMV IgM false positivity in comparison with those without CMV IgM false positivity. The week of delivery was lower in APS pregnancies with CMV IgM false positivity than APS without false positivity, but the difference did not reach statistical significance (Table 2) .
Only in PAPS pregnancies, a statistically significant difference in the rate of babies weighing 2000 g was found between patients having CMV IgM false positivity (n ¼ 2/4) and patients not having CMV IgM false positivity (n ¼ 2/37; 50% vs. 5.4%, p ¼ 0.0043).
Discussion
The relationship between autoimmune diseases and infections has long been established in the medical literature. Opportunistic infections are common in patients with autoimmune disorders: they may precede the development of the disease, contributing to the pathogenesis; they may also complicate their course of disease or even be an epiphenomenon.
On the other hand, in patients with autoimmune diseases the serological diagnosis of infections may be hampered by changes in the components of the immune response. These changes may even lead to false-positive serological tests as a result of a non-specific activation of B-lymphocytes. 6 Our report shows the relationship between CMV IgM false positivity and pregnancy outcome. To date, these data suggest for the first time that the presence of CMV IgM false positivity could represent a novel prognostic factor for poor pregnancy outcome in APS patients. Since the serology for CMV is available at the beginning of pregnancy, testing for this may also be used as an early pregnancy outcome prognostic factor. The low number of pregnancies with CMV false positivity and the use of only univariate analysis make necessary a larger prospective study to confirm the role of this finding as a novel prognostic factor for poor pregnancy outcome in APS patients.
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